Press Releases

Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application to initiate an Early Access Program for its investigational inhaled sedation therapy, providing eligible patients access...

The board of directors of Sedana Medical AB (publ) has resolved to convene an annual general meeting of shareholders to be held Thursday, 15 May 2025. Further details on the proposals can be found in the notice below. The notice is expected to be published...

Sedana Medical AB (publ) publishes its Annual Report for 2024. The Annual Report describes important events and financial information for 2024, as well as the progress the company has made on its strategic priorities during the year. “Sedana Medical...

Sedana Medical hereby invites to an investor call related to the results of the investigator initiated SESAR study today 19 March at 15:00 CET Yesterday (18 March) the investigator initiated study ”Sevoflurane for sedation in Acute Respiratory Distress...

Sedana Medical AB (publ) today issues a statement following the publication of the Investigator Initiated Study (IIS) “Sevoflurane for sedation in Acute Respiratory Distress Syndrome (ARDS)”, the SESAR study, in The Journal of American Medicine...

Primary endpoint met in both US trials and positive ex-US EBITDA excl. one-offs in Q4 Fourth quarter 2024 January-December 2024 CEO comments Sedana Medical had a successful 2024, in which we achieved our goals across our three main priorities: Positive...

Sedana Medical AB (publ) announces that its second pivotal US trial INSPiRE-ICU 2 has met its primary endpoint, and hence established non-inferiority of inhaled sedation with isoflurane compared with intravenous sedation using propofol. The safety results...

Sedana Medical AB (publ) announces that Sedaconda® (isoflurane) has received an additional year of market protection, extending the protection period until 2032. The decision is based on the regulatory assessment that the recently approved paediatric...

Sedana Medical AB (publ) plans to present its interim report for the fourth quarter of 2024 on Thursday February 13 at 13:30 CET. According to the financial calendar, Sedana Medical plans to publish the interim report for the fourth quarter 2024 on Thursday...

Sedana Medical AB (publ) announces that its first pivotal US trial INSPiRE-ICU 1 has met its primary endpoint: to prove that inhaled sedation with isoflurane is an effective sedation method by establishing non-inferiority compared with intravenous sedation...